[Correspondence] Daratumumab–lenalidomide and the immunosuppressive budget in myeloma

Salomon Manier and colleagues show that, in patients aged 65 years or older with newly diagnosed multiple myeloma selected for frailty, a regimen of lenalidomide plus daratumumab with dexamethasone confined to the first two cycles achieves markedly longer progression-free survival than continuous lenalidomide–dexamethasone, with an accompanying overall survival benefit and no clear excess of serious infections.1 For a population in…